Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.49 |
| ▸ | MTOR | P42345 | 10/20 | 0.49 |
| ▸ | AKT1 | P31749 | 10/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651590 | 0.88 | PIK3CA (0.59) | PIK3CAMTORAKT1PIK3CGPIK3CD | |
| SCHEMBL1650409 | 0.83 | KMT2A (0.51) | PIK3CAPIK3CGDYRK1AADORA1MEN1 | |
| SCHEMBL1651318 | 0.81 | TP53 (0.44) | PIK3CAMTORAKT1PIK3CGPIK3CD | |
| SCHEMBL1653654 | 0.81 | SMN1; SMN2 (0.62) | PIK3CAPIK3CGPIK3CBDYRK1AADORA1 | |
| SCHEMBL1651603 | 0.80 | DYRK1A (0.50) | PIK3CAPIK3CGDYRK1AADORA1 | |
| SCHEMBL1650997 | 0.80 | DYRK1A (0.60) | PIK3CAPIK3CGPIK3CDPIK3CBDYRK1A | |
| SCHEMBL1622027 | 0.78 | PIK3CA (0.60) | PIK3CAMTORAKT1MEN1KMT2A | |
| SCHEMBL1650938 | 0.77 | PIK3CA (0.51) | PIK3CAPIK3CGDYRK1AADORA1 | |
| SCHEMBL1619401 | 0.76 | PIK3CA (0.59) | PIK3CAMTORAKT1PIK3CGPIK3CD | |
| SCHEMBL1650746 | 0.76 | PIK3CA (0.51) | PIK3CAMTORPIK3CGPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | claimed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885AKT1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.